4640 Results

People

  1. Saltz
    Saltz
  2. O'Reilly
    O'Reilly
  3. Abou-Alfa
    Abou-Alfa
  4. Kelsen
    Kelsen
  5. Ilson
    Ilson
  6. Kemeny
    Kemeny
  7. Janjigian
    Janjigian
  8. Reidy
    Reidy
  9. Jarnagin
    Jarnagin
  10. D'Angelica
    D'Angelica

Groups

  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)
  7. Epidemiology and Biostatistics (828)
  8. GSK Faculty (793)
  9. Department of Pathology and Laboratory Medicine (723)
  10. Biostatistics Service (661)
  1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Organ preservation, compliance and toxicity in rectal cancer patients treated with total neoadjuvant therapy: A post hoc analysis of the of the OPRA phase II trial
    Meeting Abstract

    Verheij, F. S.; Omer, D. M.; Lin, S. T.; Yuval, J. B.; Thompson, H. M.; Kim, J.; Valdivieso, S. C.; Qin, L. X.; Wu, A. J.; Saltz, L. B.; more...
    Annals of Surgical Oncology (2023)

    Fulltext@MSK | Save
  • Adjuvant chemotherapy for resected intrahepatic cholangiocarcinoma confers no survival advantage
    Meeting Abstract

    Sharib, J.; Liu, A.; McIntyre, S.; Rhodin, K. E.; Kemeny, N. E.; Cercek, A.; Harding, J. J.; Abou-Alfa, G. K.; Soares, K. C.; Wei, A. C.; more...
    Annals of Surgical Oncology (2023)

    Fulltext@MSK | Save
  • Genetic heterogeneity of intrahepatic cholangiocarcinoma: Implications for outcome
    Meeting Abstract

    Song, Y.; Boerner, T.; Drill, E.; Shin, P.; Cercek, A.; Kemeny, N. E.; Abou-Alfa, G. K.; Iacobuzio-Donahue, C.; Schultz, N.; Walch, H.; more...
    Annals of Surgical Oncology (2023)

    Fulltext@MSK | Save
  • Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)
    Meeting Abstract

    Bullock, A.; Fakih, M.; Gordon, M.; Tsimberidou, A.; El-Khoueiry, A.; Wilky, B.; Pimentel, A.; Margolin, K.; Mahadevan, D.; Balmanoukian, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: Sensitivity analysis of survival from the NAPOLI 3 trial
    Meeting Abstract

    Wainberg, Z.; Melisi, D.; Macarulla, T.; Cid, R. P.; Chandana, S.; de la Fouchardiere, C.; Dean, A.; Kiss, I.; Lee, W.; Goetze, T.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
    Meeting Abstract

    Sangro, B.; Chan, S.; Kelley, R.; Lau, G.; Kudo, M.; Sukeepaisarnjaroen, W.; De Toni, E.; Furuse, J.; Kang, Y.; Galle, P.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes and a prognostic classifier in 130 patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade
    Meeting Abstract

    Randon, G.; Aoki, Y.; Cohen, R.; Nasca, V.; Klempner, S.; Maron, S.; Cerantola, R.; Fornaro, L.; Ambrosini, M.; Manca, P.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E+C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis
    Meeting Abstract

    Tabernero, J.; Van Cutsem, E.; Yoshino, T.; Yaeger, R.; Wasan, H.; Desai, J.; Ciardiello, F.; Alkuzweny, B.; Zhang, X.; Guenzil, C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Quantitative risk-benefit assessment of ivosidenib compared to placebo in patients with IDH1-mutated intrahepatic cholangiocarcinoma: Phase 3 ClarIDHy trial
    Meeting Abstract

    Valle, J.; Abou-Alfa, G.; Kelley, R.; Lowery, M.; Shroff, R.; Bian, Y.; Saint-Hilary, G.; Liu, H.; Teng, Z.; Hua, Z.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes in advanced hepatocellular carcinoma (HCC) patients (pts) treated with immune checkpoint inhibitors (ICI)
    Meeting Abstract

    Cowzer, D.; Capanu, M.; Keane, F.; Khalil, D.; Shia, J.; Do, R.; Chou, J.; Walch, H.; El Dika, I.; Yaqubie, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save